IPO Guru
Dilip Davda

Dilip Davda

No description available for this analyst.

✅ Reliable Analyst
66 Score / 100

Performance Dashboard

Reliable analyst with a solid record of good picks.

Based on 13 IPO reviews in the last 12 months.

Accuracy
100%
Return Quality
75%
Consistency
54%
Horizon
89%

⚠️ Disclaimer: Past results are not guaranteed for future. This score only shows how well the analyst performed in the last 1 year. Use it for research only.

Review History

13 Total Reviews
IPO Name Verdict Listing Gain % Total Gain % Report
Biopol Chemicals (SME) Avoid - - -
ICICI Prudential AMC (Mainboard) Apply 20.09% 41.13% -
Aequs (Mainboard) Not rated 12.90% 13.10% -
Meesho (Mainboard) Not rated 0.00% 33.41% -
Corona Remedies (Mainboard) Not rated 38.42% 38.85% -
Wakefit Innovations (Mainboard) Not rated 0.00% -7.20% -
Park Medi World (Mainboard) Not rated -1.98% -2.87% -
Nephrocare Health Services (Mainboard) Not rated 6.52% 14.43% -
KSH International (Mainboard) Not rated -3.65% -6.05% -
Gujarat Kidney & Super Speciality (Mainboard) Not rated 5.26% -6.66% -
Shadowfax Technologies (Mainboard) Not rated -9.19% -6.39% -
Amagi Media Labs (Mainboard) Not rated -12.19% 3.42% -
Bharat Coking Coal (Mainboard) Not rated 95.65% 62.87% -